ORMP (oramed.com) Prakiraan pendapatan perusahaan
The estimated future sales metric correlates with the strategic alliances of Oramed Pharmaceuticals (ORMP) in the field of oral insulin. The 0.00 mark characterizes this parameter, while management under Nadav Kidron ensures the financial stability of assets. The company's growth relies on the development of the POD platform, technology licensing, and expansion into the MASH and diabetes segments.
Rincian metrik lan analitis perusahaan Oramed Pharmaceuticals (ORMP)
- nilai saham lan prakiraan konsensus rega:
- indikator valuasi pasar bisnis:
- data ekuitas miturut neraca:
- data tingkat utang lan likuiditas finansial:
Utang marang Ekuitas Oramed Pharmaceuticals|ORMP - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Oramed Pharmaceuticals|ORMP - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Oramed Pharmaceuticals Inc.|ORMP - Tanggungan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Oramed Pharmaceuticals|Likuiditas cepet oramed.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
ORMP - Bathi sawise pajeg|Proyeksi bathi mangsa ngarep Oramed Pharmaceuticals|ORMP - Nilai perusahaan marang bathi resik|Pangali Forward P/E oramed.com|ORMP - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Oramed Pharmaceuticals|ORMP - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Oramed Pharmaceuticals|ORMP - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan oramed.com|ORMP - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Oramed Pharmaceuticals
- informasi babagan volume dodolan lan pendapatan:
Analisis kabeh metrik perusahaan:oramed.com
Future sales volume represents the discounted value of the issuer's expected revenue inflows. By analyzing the projected sales revenue, the investor sees the current calculated value of 0.00. This metric aggregates future cash flows discounted to the present day, accounting for risks. For Oramed Pharmaceuticals (ORMP), this reflects the commercialization potential of developments from the Israeli R&D center. The use of contract manufacturing organizations minimizes operational disruptions, stabilizing this fundamental valuation.
Karo sapa Oramed Pharmaceuticals saingan
Prakiraan volume dodolan HLN|KVUE (Kenvue Inc) - Pendapatan mangsa ngarep perusahaan|Verona Pharma Corp - Volume dodolan mangsa ngarep perusahaan|Prakiraan volume pendapatan perusahaan MENS (Jyong Biotech Ltd)|ligand.com - Prakiraan volume dodolan|amneal.com (AMRX) - Volume dodolan mangsa ngarep perusahaan|Perrigo (PRGO) - Prakiraan pendapatan perusahaan|ALVO (Alvotech S.A.) - Prakiraan pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan LQDA|Prakiraan volume dodolan Galapagos Corp|Prakiraan pendapatan perusahaan ANI Pharma (ANIP)|Prakiraan volume dodolan MannKind Corporation (MNKD)|Prakiraan pendapatan perusahaan Amphastar Pharmaceuticals Inc AMPH|Prakiraan volume dodolan Pacira PCRX|ARS Pharmaceuticals Inc - Prakiraan volume dodolan|TBPH - Prakiraan volume dodolan|AQST (Aquestive Therapeutics) - Volume dodolan mangsa ngarep perusahaan|scPharmaceuticals, Inc. (SCPH) - Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan TECX|Prakiraan volume dodolan Tonix Pharma|Volume dodolan mangsa ngarep perusahaan SXTC (SXT Pharmaceuticals)|EPRX: Pendapatan sing dikarepake perusahaan|BioHarvest Sciences - Volume dodolan mangsa ngarep perusahaan|EXOZ: Prakiraan pendapatan perusahaan|ENTX - Prakiraan pendapatan perusahaan|HYFT: Prakiraan pendapatan perusahaan|ABVC BioPharma, Inc (ABVC) - Prakiraan pendapatan perusahaan|Cumberland Pharma - Pendapatan mangsa ngarep perusahaan|QNTM (Quantum BioPharma Corp) - Prakiraan volume dodolan|FibroGen, Inc. - Pendapatan sing dikarepake perusahaan|Prakiraan volume dodolan TELO|Dodolan mangsa ngarep perusahaan Rani Therapeutics Holdings, Inc.|Prakiraan pendapatan perusahaan Synergy CHC Corp. SNYR|Prakiraan volume dodolan rallybio.com RLYB|Lexaria Bioscience Corp. - Prakiraan volume dodolan|PULM: Prakiraan pendapatan perusahaan|PTHL (ftzy.com.cn) - Volume dodolan mangsa ngarep perusahaan|APM: Prakiraan volume pendapatan perusahaan|LYRA (Lyra Therapeutics Inc) - Prakiraan volume dodolan|Prakiraan pendapatan perusahaan IBO (Impact BioMedical)|Volume dodolan mangsa ngarep perusahaan TNFA (TNF Pharmaceuticals)|Prakiraan volume dodolan cbdMD Corp (YCBD)|Prakiraan volume dodolan PRFX (PainReform)|Dodolan mangsa ngarep perusahaan Auris Medical (CYTO)|LIPO - Prakiraan pendapatan perusahaan|Optinose (OPTN) - Volume dodolan mangsa ngarep perusahaan|Pieris (PIRS) - Prakiraan pendapatan perusahaan|Pendapatan sing dikarepake perusahaan PROC (Procaps Group S.A.)|Volume dodolan mangsa ngarep perusahaan PTPI|QLI: Pendapatan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan acelyrin.com (SLRN)|TFFP (TFF Pharma) - Pendapatan mangsa ngarep perusahaan
